English
日本語ミッション
MISSION
Pioneering a new frontier in reconstructive
and regenerative medicine.
We are dedicated to advancing reconstructive and regenerative medicine through pioneering research and development centered on extracellular vesicle (EV) technology. Focusing on urology and extending to trauma, disaster, and combat medicine, we strive to deliver innovative, minimally invasive medical solutions that help restore lost function and improve quality of life, empowering people to live with dignity and resilience.
研究開発
RESEARCH&
DEVELOPMENT
Pioneering Regenerative Solutions through Extracellular Vesicle Innovation
At Advanced RegenTech Corp., we are dedicated to pioneering next-generation regenerative therapies through the clinical application of extracellular vesicle (EV) technology. By leveraging the powerful biological properties of EVs—especially those derived from mesenchymal stem cells—we aim to deliver innovative treatments across urology, trauma medicine, and mucosal tissue regeneration.
Collaborative Research with Juntendo University
As part of translational research toward the clinical application of extracellular vesicle-based urethral regenerative therapy, Advanced RegenTech Corp., through its parent company JHD Co., entered into a collaborative research agreement with Juntendo University in April 2024. Together, we are advancing a broad range of studies from basic science to clinical application. Through this partnership, we aim to deepen our understanding of EV mechanisms and create new treatment options in the field of urological regenerative medicine.
Key Research Focus Areas
Urethral Regeneration
Development of Transurethral EV Therapy for Urethral Injury and Refractory Strictures
We are developing a minimally invasive, transurethral exosome-based therapy aimed at regenerating the urethral epithelium and suppressing fibrosis following injury or surgical intervention. This approach has the potential to significantly reduce recurrence and improve patient quality of life.
Oral Mucosal Regeneration
EV-Based Therapeutics for Oral Ulcers and Inflammation after Graft Harvesting
In urethral reconstruction, tissue grafts such as oral mucosa or penile skin are used to replace strictured segments. Successful outcomes depend not only on graft engraftment but also on creating a regenerative microenvironment. We are developing EV-based formulations that promote epithelial proliferation and control inflammation following oral mucosal graft harvesting, aiming to support rapid healing and reduce patient discomfort.
Disaster & Tactical Medicine
Developing EV-Based Strategies for Limb Preservation in Trauma, Disaster, and Combat Settings
Amid recent geopolitical crises—particularly the war in Ukraine—many soldiers have suffered severe genitourinary injuries, resulting in substantial reductions in quality of life. Reconstructive urology has been shown to support not only physical recovery but also psychosocial reintegration, with patients reporting improvements in daily activity and social interaction. To address these critical unmet needs, ART is actively developing EV-based therapies for functional preservation and reconstruction of the urogenital system in trauma, disaster, and battlefield medicine.
会社概要
COMPANY
Company
Name
Advanced RegenTech Corp.
Established
January 2025
Representative
Daisuke Watanabe, President & CEO
Address
1-7-11 Azabujuban, Minato-ku, Tokyo, Japan
TEL
+81-3-6455-4278
Company
Name
Contracted services for processing, manufacturing, culturing, storage, and delivery of tissues and cells
Capital
JPY 1,000,000
顧問
ADVISOR
Advisor / Physician, M.D., Ph.D.
Mizushima Akio, M.D., Ph.D.
Career
1984
Graduated from Juntendo University School of Medicine
1990
Ph.D. in Medicine, Juntendo University Graduate School of Medicine
Studied at the University of Edinburgh, UK (Japan Society of Anesthesiologists / Sasakawa Fellowship)
1996
Studied at The Hospital for Sick Children, Toronto, Canada (Japanese Society of Pediatric Anesthesiology / Sata Fellowship)
2000
Associate Professor, Department of Anesthesiology, Juntendo University Urayasu Hospital
2013
Professor, Department of Palliative Medicine, Juntendo University Graduate School of Medicine
Director, Palliative Care Center, Juntendo University Hospital
2025
Specially Appointed Professor & Emeritus Professor, Department of Palliative Medicine, Juntendo University Graduate School of Medicine (current position)
Advisor / Physician, M.D., Ph.D.
Horiguchi Akio, M.D., Ph.D.
Career
1994
Graduated from Keio University School of Medicine
2004
Ph.D. in Medicine, Keio University Graduate School of Medicine
Studied at Cornell University, USA (Department of Urology)
2018
Associate Professor, Department of Urology, National Defense Medical College
2021
Director, Department of Trauma and Reconstructive Surgery, National Defense Medical College
2025
Professor, Department of Reconstructive Surgery, Center for Trauma, Burns, and Disaster Medicine, National Defense Medical College Hospital (current position)
お問い合わせ